Literature DB >> 8543175

Structural organization and expression of the mouse gene encoding alpha-galactosidase A.

T Ohshima1, G J Murray, J W Nagle, J M Quirk, M H Kraus, N W Barton, R O Brady, A B Kulkarni.   

Abstract

alpha-Galactosidase A (alpha-D-galactoside galactohydrolase, EC 3.2.1.22; alpha GalA) is a lysosomal enzyme that hydrolyses the alpha-D-galactosyl residues from glycosphingolipids. Fabry disease, an inhibited X-linked recessive human metabolic disorder, results from a mutation in the alpha GalA gene at Xq22. As a prerequisite for generating a mouse model of Fabry disease by gene targeting, we have isolated and characterized the mouse alpha GalA gene and cDNA. A cloned mouse alpha GalA cDNA encoded a putative precursor protein of 419 amino acids (aa), including a 31-aa signal peptide (SP). The deduced aa sequence showed high homology (79%) with the human alpha GalA protein. Nucleotide sequence analysis of genomic clones revealed that the overall structure and organization of the gene was very similar to that of human alpha GalA. All exon-intron splice junctions conformed to the GT/AG consensus sequence. Comparison of genomic and cDNA sequences revealed the occurrence of two putative polyadenylation signals whose alternative use results in the two mouse alpha GalA transcripts of 1.4 and 3.6 kb. The 5'-flanking region of mouse alpha GalA had no typical TATA box. Several putative promoter-associated elements including Sp1, AP1 and a potential cAMP-responsive element (CRE) were identified. Northern blot analysis revealed the widespread tissue distribution of mouse alpha GalA transcripts. Lower expression levels, however, were observed in some tissues, implying tissue-specific differences in alpha GalA promoter function.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8543175     DOI: 10.1016/0378-1119(95)00592-7

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  7 in total

1.  alpha-Galactosidase Aga27A, an enzymatic component of the Clostridium josui cellulosome.

Authors:  Sadanari Jindou; Shuichi Karita; Emi Fujino; Tsuchiyoshi Fujino; Hidenori Hayashi; Tetsuya Kimura; Kazuo Sakka; Kunio Ohmiya
Journal:  J Bacteriol       Date:  2002-01       Impact factor: 3.490

2.  Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.

Authors:  S C Jung; I P Han; A Limaye; R Xu; M P Gelderman; P Zerfas; K Tirumalai; G J Murray; M J During; R O Brady; P Qasba
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

3.  Murine acid alpha-glucosidase: cell-specific mRNA differential expression during development and maturation.

Authors:  E Ponce; D P Witte; R Hirschhorn; M L Huie; G A Grabowski
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

4.  alpha-Galactosidase A deficient mice: a model of Fabry disease.

Authors:  T Ohshima; G J Murray; W D Swaim; G Longenecker; J M Quirk; C O Cardarelli; Y Sugimoto; I Pastan; M M Gottesman; R O Brady; A B Kulkarni
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

5.  Pain related channels are differentially expressed in neuronal and non-neuronal cells of glabrous skin of fabry knockout male mice.

Authors:  Jarmila Lakomá; Roberto Rimondini; Vincenzo Donadio; Rocco Liguori; Marco Caprini
Journal:  PLoS One       Date:  2014-10-22       Impact factor: 3.240

6.  Increased expression of Trpv1 in peripheral terminals mediates thermal nociception in Fabry disease mouse model.

Authors:  Jarmila Lakomá; Roberto Rimondini; Antonio Ferrer Montiel; Vincenzo Donadio; Rocco Liguori; Marco Caprini
Journal:  Mol Pain       Date:  2016-08-16       Impact factor: 3.395

7.  Affective and cognitive behavior in the alpha-galactosidase A deficient mouse model of Fabry disease.

Authors:  Lukas Hofmann; Franziska Karl; Claudia Sommer; Nurcan Üçeyler
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.